Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis

28 August 2026 · By · Wire by Fusion42

Published

28 August 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at biospace.com →

◆ Verified

Fusion42 · 28 August 2026 · Fusion42 review

Roivant's LISRAYA (brepocitinib) has received FDA approval as the first targeted therapy for adults with dermatomyositis, a rare autoimmune disease, showing significant efficacy and steroid-sparing benefits in the largest clinical trial to date.

This Wire brief sits within Fusion42's coverage of Medtech, and 4 sources have reported it between 28 Aug 2026 and 4 Sep 2026.

◆ ◆ The Wire takeaway

The FDA approval of LISRAYA opens a new market for targeted autoimmune treatments in dermatomyositis patients. You should explore partnerships with specialists and consider early engagement with patient support programmes to gain market traction.

◆ Coverage

4 sources · first reported 28 Aug 2026 · latest 4 Sep 2026

◆ Related on Wire

◆ Topics

MedtechFDA-approvalautoimmunedermatomyositisdrug-innovationRoivant